What happened to the Neovasc stock price?
The Neovasc Inc. stock price fell by -0.30% on the last day (Friday, 31st Dec 2021) from $0.47 to $0.47. During the day the stock fluctuated 7.51% from a day low at $0.45 to a day high of $0.49.
Is neneovasc a good stock to buy?
Neovasc has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
What is the Neovasc reducer?
The medical device company revealed that its Neovasc Reducer device that was designed to treat refractory angina was granted a Breakthrough Device designation by the FDA.
Where can I buy Neovasc (nvcn)?
Shares of NVCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Neovasc's stock price today?
See more
Is neovasc a good investment?
The 1 analysts offering 12-month price forecasts for Neovasc Inc have a median target of 98.42, with a high estimate of 98.42 and a low estimate of 98.42. The median estimate represents a +1,602.79% increase from the last price of 5.78.
What kind of company is NVCN?
Neovasc Inc (NASDAQ:NVCN) engages in the development, manufacture and marketing of medical devices. It focuses on Neovast Tiara and Neovasc Reducer products. The company was founded on November 2, 2000 and is headquartered in Richmond, Canada.
Did NVCN reverse split?
The first split for NVCN took place on September 21, 2018. This was a 1 for 100 reverse split, meaning for each 100 shares of NVCN owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 10 share position following the split.
What is neovasc reducer?
NEOVASC REDUCER Reducer is a small, balloon-expandable, hourglass-shaped device that establishes a narrowing in the coronary sinus. The resulting increase in back pressure redistributes blood into the ischemic myocardium.
Is Neovasc a buy right now?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neovasc in the last year. There are currently 1 buy rating for the stock....
Are investors shorting Neovasc?
Neovasc saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 5,300 shares, a drop of 76.8% from...
When is Neovasc's next earnings date?
Neovasc is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022. View our earnings forecast for Neovasc .
How were Neovasc's earnings last quarter?
Neovasc Inc. (NASDAQ:NVCN) announced its quarterly earnings data on Thursday, March, 10th. The medical equipment provider reported ($2.25) earnings...
When did Neovasc's stock split? How did Neovasc's stock split work?
Shares of Neovasc reverse split before market open on Friday, April 29th 2022. The 1-25 reverse split was announced on Friday, April 29th 2022. The...
What price target have analysts set for NVCN?
1 analysts have issued 1-year price targets for Neovasc's stock. Their forecasts range from $125.00 to $125.00. On average, they expect Neovasc's s...
Who are Neovasc's key executives?
Neovasc's management team includes the following people: Mr. Fredericus A. Colen , Pres, CEO & Director (Age 70, Pay $2.59M) Mr. Christopher Cla...
Who are some of Neovasc's key competitors?
Some companies that are related to Neovasc include TransEnterix (TRXC) , Biostage (BSTG) , Pro-Dex (PDEX) , Titan Medical (TMDI) , Spectral Me...
What other stocks do shareholders of Neovasc own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Neovasc investors own include Biopharmx (BPMX) , Allstate...
How many shares of Neovasc stock are there after the split?
Where is Neovasc located?
An investor that had 100 shares of Neovasc stock prior to the reverse split would have 1 shares after the split.
What is the NVCN symbol?
It focuses on Neovast Tiara and Neovasc Reducer products. The company was founded on November 2, 2000 and is headquartered in Richmond, Canada.
What is the P/E ratio of Neovasc?
Neovasc trades on the NASDAQ under the ticker symbol "NVCN."
Is Neovasc a buy or sell company?
The P/E ratio of Neovasc is -1.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Who bought NVCN stock?
Neovasc has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Does Neovasc pay dividends?
NVCN stock was acquired by a variety of institutional investors in the last quarter, including U.S. Capital Wealth Advisors LLC, and UBS Group AG.
What is a neovasc?
Neovasc does not currently pay a dividend.
Is SVB Leerink a good buy?
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets cardiovascular products worldwide. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company also provides Peripatch biological tissue products that are used as components in third-party medical products, such as transcatheter heart... Read more
Is Neovasc Inc. a negative stock?
SVB Leerink is very positive about NVCN and gave it a "Buy" rating on Mar 14, 2021. The price target was set to $2.00 .
Is Neovasc stock a buy or sell signal?
Neovasc Inc. holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Buy to a Sell candidate.
About Neovasc
A buy signal was issued from a pivot bottom point on Thursday, November 18, 2021, and so far it has risen 9.77%. Further rise is indicated until a new top pivot has been found. Some negative signals were issued as well, and these may have some influence on the near short-term development. The Neovasc Inc. stock holds a buy signal from the short-term moving average; at the same time, however, the long-term average holds a general sell signal. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. On further gains, the stock will meet resistance from the long-term moving average at $0.74. On a fall, the stock will find some support from the short-term average at $0.71. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sell signal and strengthen the general signal. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell along with the price during the last trading day, which is technical positive. One should, however, note that this stock may have low liquidity in periods, which increases the general risk.
3.5 Analyst's Opinion
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace.
Is Neovasc a buy right now?
Neovasc has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
When is Neovasc's next earnings date?
1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Neovasc in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Neovasc stock. View analyst ratings for Neovasc or view top-rated stocks.
What price target have analysts set for NVCN?
Neovasc is scheduled to release its next quarterly earnings announcement on Thursday, March 10th 2022. View our earnings forecast for Neovasc.
Who are some of Neovasc's key competitors?
1 brokerages have issued 1 year target prices for Neovasc's stock. Their forecasts range from C$5.00 to C$5.00. On average, they expect Neovasc's stock price to reach C$5.00 in the next year.
What is Neovasc's stock symbol?
Some companies that are related to Neovasc include Global X E-commerce ETF (EBIZ), Overlay Shares Core Bond ETF (OVB), WesternZagros Resources ULC, (WZR), 298835 (GBU.TO) (GBU), Advantis (ADVT), AdvisorShares Dorsey Wright FSM All Cap World ETF (DWAW), VictoryShares Nasdaq Next 50 ETF (QQQN), SP Funds S&P 500 Sharia Industry Exclusions ETF (SPUS), iShares MSCI New Zealand ETF (ENZL), First Trust NASDAQ ABA Community Bank Index Fund (QABA), FBR & Co.